On December 5, 2025, Aimed Alliance’s Counsel, Michael Barnes, published a new opinion piece titled “Trump Administration Took Decisive Action…
Aimed Alliance has released a new fact sheet explaining the role of the U.S. Trade Representative (USTR) in shaping international…
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) announced a new drug payment initiative aimed at addressing…
On October 13, 2025, California Governor Gavin Newsom signed Senate Bill 243 into law, establishing the first comprehensive state law…
A new article by Fierce Healthcare titled “A new wave of middlemen offers ‘alternative funding’ for specialty drugs. Patients bear…
The 2026 Open Enrollment period is fast approaching! The 2026 Open Enrollment period for Medicare Advantage plans is October 15,…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf regarding his special session bill, “Prescription Drug Benefit Information Transparency” (HB25B-1012).…
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…
On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the…
Aimed Alliance submitted a comment to the Oregon Prescription Drug Affordability Board (PDAB) urging it to maintain a careful, evidence-based…